TXMD vs PGNY vs DARE vs ANIP vs EVAX

For growth investors, Evaxion Biotech A/S (EVAX) is the stronger pick with 125.

8% revenue growth year-over-year, versus -99. 7% for Daré Bioscience, Inc. (DARE). ANI Pharmaceuticals, Inc. (ANIP) offers the better valuation at 25. 3x trailing P/E (9. 2x forward), making it the more compelling value choice. Analysts rate Progyny, Inc. (PGNY) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, ANI Pharmaceuticals, Inc.

(ANIP) is the cheapest at 25. 3x versus Progyny, Inc. at 29. 5x. On forward P/E, ANI Pharmaceuticals, Inc. is actually cheaper at 9. 2x.

Over the past 5 years, ANI Pharmaceuticals, Inc.

(ANIP) delivered a total return of +117. 4%, compared to -98. 8% for Evaxion Biotech A/S (EVAX). Over 10 years, the gap is even starker: ANIP returned +84. 7% versus TXMD's -99. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Daré Bioscience, Inc.

(DARE) is the lower-risk stock at 0. 48β versus Evaxion Biotech A/S's 1. 29β — meaning EVAX is approximately 168% more volatile than DARE relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 60% for ANI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Evaxion Biotech A/S (EVAX) is pulling ahead at 125.

8% versus -99. 7% for Daré Bioscience, Inc. (DARE). On earnings-per-share growth, the picture is similar: ANI Pharmaceuticals, Inc. grew EPS 419. 2% year-over-year, compared to 14. 0% for Progyny, Inc.. Over a 3-year CAGR, ANIP leads at 40. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ANI Pharmaceuticals, Inc.

(ANIP) is the more profitable company, earning 8. 9% net margin versus -414. 3% for Daré Bioscience, Inc. — meaning it keeps 8. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ANIP leads at 12. 6% versus -2396. 9% for DARE. At the gross margin level — before operating expenses — TXMD leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, ANI Pharmaceuticals, Inc.

(ANIP) trades at 9. 2x forward P/E versus 16. 4x for Progyny, Inc. — 7. 1x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGNY: 60. 8% to $30. 80.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Daré Bioscience, Inc.

(DARE) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 48)). Both have compounded well over 10 years (DARE: -99. 0%, EVAX: -99. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TXMD is a small-cap high-growth stock; PGNY is a small-cap quality compounder stock; DARE is a small-cap quality compounder stock; ANIP is a small-cap high-growth stock; EVAX is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.